Service practice
Innovation & Product Strategy
Practice overview
How this practice runs.
Innovation is the most expensive gamble in the corporate portfolio. For the Fortune 1000, a misaligned product launch in 2026 isn't just a marketing failure; it is an institutional setback that can erase billions in enterprise value. Our service acts as your Commercial Insurance…
What we do
Strategic capabilities.
The concrete deliverables and analytical work that fall inside this practice.
-
Synthetic Market Simulations
Utilizing AI-calibrated "Digital Wind Tunnels" to stress-test thousands of pricing and feature configurations before physical prototyping.
-
UX/CX Ecosystem Mapping
Immersion studies into high-complexity environments, from MedTech diagnostic interfaces to Software-Defined Vehicle (SDV) cockpits.
-
Value-Based Pricing Architecture
Moving beyond "Cost-Plus" models to isolate the exact utility-driven price ceiling in volatile or inflationary markets
-
Portfolio Rationalization
Auditing the R&D pipeline to identify "Zombie Projects" and reallocate capital toward high-alpha breakthroughs.
Selected engagements
Case studies from this practice.
Anonymised engagement summaries — the question the client was answering, and what we shipped.
-
01
ADAS Evolution & Autonomous Roadmapping (Automotive Tech)
-
02
The Challenge
A global Tier-1 automotive supplier faced "feature stagnation." With Level 2+ autonomy becoming commoditized, they needed to validate a $500M R&D commitment to Level 3/4 "Experience Features" without clear data on consumer "Willingness-to-Pay."
-
03
The Intelligence Lever
We deployed a Multi-Horizon Innovation Framework, combining synthetic simulations of 30+ feature configurations with immersive VR User Clinics. We mapped liability "Green-Zones" across the US, EU, and China to identify where the SaaS model met the least legal resistance.
-
04
The Enterprise Outcome
Identified a "Value Gap" in In-Cabin Wellness-to-Safety Integration. The client pivoted R&D to a proprietary "Driver Vitality" suite, securing three major "Design Wins" with global OEMs and a $1.2B projected revenue pipeline.
-
05
Multi-Cancer Early Detection (MCED) Strategic Alliance (Biotech)
-
06
The Challenge
A disruptive Biotech firm developed a high-sensitivity MCED assay identifying 50+ cancer types. Despite technical superiority, they lacked the global distribution and "Payer-Negotiation" muscle required to scale.
-
07
The Intelligence Lever
We executed a Partner-Fit Matrix analysis, auditing 15 potential suitors across Big Pharma and MedTech. We performed due diligence on "Synergy vs. Cannibalization" risks and conducted double-blind interviews with Global Lab Chains to determine "Trust-Equity."
-
08
The Enterprise Outcome
Identified a Fortune 500 Lab Diagnostics giant as the optimal partner. We drafted a Negotiation Playbook that led to a $250M+ co-marketing agreement, accelerating time-to-market by 3 years and securing immediate access to 10,000+ clinical sites.
Working with us
Ready to scope a Innovation & Product Strategy engagement?
A 30-minute scoping call is free. We'll write the SOW only after we've agreed on the decision the work needs to support.